Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place.
Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of AJMC®'s The Center for Biosimilars®, highlights recent progress, how the US market compares with Europe, and what remains to be seen.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
Stakeholders Weigh In on the Key Biosimilar Developments of 2018
Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca
FDA Releases Biosimilar Action Plan
Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen
Pfizer Becomes Latest to Settle With AbbVie Over Humira
Read more about the stories in this podcast:
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024
January 14th 2024Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen